ArticleInterdisciplinary cardiovascular and thoracic surgery2025
Understanding barriers to adjuvant therapy in resected non-small cell lung cancer: A multicenter analysis.
Article in Interdisciplinary cardiovascular and thoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate variables associated to not receiving adjuvant therapy in patients with resected pathological IB-IIIA NSCLC from a national registry.
methodsPatients who had lung resections were analyzed retrospectively for stages IB-III from 2009-2023, sourced from a multicentre registry. Uni/Multivariable logistic regression was performed, and a predictive tool was created to predict adjuvant therapy probability and cut-off values were determined through ROC analysis. The model's discrimination, performance and fit were evaluated using AUC-ROC, sensitivity/specificity and Hosmer-Lemeshow test respectively.
resultsOf the 427 patients analyzed, the mean age was 65.4 years and 83.1% were treated under public insurance. 38.4% of patients received adjuvant chemotherapy after surgery. Multivariable analysis identified older age (OR = 1.06, p < 0.001), histological subtype (OR = 21.3, p < 0.001), public insurance (OR = 2.65, p = 0.006), stage I-B (OR = 8.10, p = 0.002), and negative lymph node status (OR = 3.34, p < 0.001) as independent factors associated with not receiving adjuvant therapy. Using the final equation, a calculated probability > 42.5% categorizes a patient for exclusive surgical intervention. The model's performance yielded an AUC of 0.833, with a sensitivity of 90.2%. The Hosmer-Lemeshow test resulted in a p ≥ 0.05.
conclusionsUnderutilization of adjuvant therapy in NSCLC is influenced by age, insurance type, and pathological factors. Public insurance status indicates healthcare access but does not fully capture social disparities. The absence of race, income, and geographic data limits broader analysis. Our model identifies patients at risk of treatment omission, aiding targeted interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.